Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors

@article{Kobayashi2004SafetyAP,
  title={Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors},
  author={Hiroyuki Kobayashi and S. Gail Eckhardt and Jennifer A. Lockridge and Mace L. Rothenberg and Alan B. Sandler and Cindy L. O’Bryant and Wendy Cooper and Scott N. Holden and Roger Aitchison and Nassim Usman and Maurice J. Wolin and Michele Basche},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2004},
  volume={56},
  pages={329-336}
}
PurposeRPI.4610 (ANGIOZYME) is a chemically stabilized ribozyme targeting vascular endothelial growth factor receptor 1. [] Key MethodMethodsThe study used a sequential treatment design evaluating a single dose level for all three drugs: paclitaxel 175 mg m−2 and carboplatin AUC=6 on day 1 of a 21-day cycle, and RPI.4610 100 mg m−2 day−1 beginning on day 8 and continuing daily thereafter.
An open‐label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer
TLDR
The authors' trial evaluated the efficacy of RPI.4610 in the treatment of patients with progressive MBC and found it to be a well‐tolerated agent with clinical activity in solid tumors.
Angiogenesis inhibitors in lung cancer: a promise fulfilled.
TLDR
This trial demonstrated an improvement in overall survival among patients who received bevacizumab in comparison with those who received carboplatin and paclitaxel alone, and issues relevant to angiogenesis inhibition in the treatment of non-small-cell lung cancer are highlighted.
New agents for treatment of advanced transitional cell carcinoma.
  • F. Perabo, S. Müller
  • Biology, Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2007
TLDR
The need for development of new and tolerable agents is urgent as some new active chemotherapeutic as new platinum compounds (oxaliplatin, lobaplatin), gallium nitrate, ifosfamide, the antifolates piritrexim and pemetrexed are highlighted.
Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics
TLDR
This review focuses on the immunomodulatory properties of various types of therapeutic nucleic acid concepts, and the most commonly observed immunological and hematological toxicities for various NAT classes.
VEGF INHIBITORS FOR CANCER THERAPY
TLDR
Clinical trials have anti-VEGF therapies are effective in reducing tumor size, metastasis and blood vessel formation and will expand the potential for combinatorial therapies.
Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
  • J. Homsi, A. Daud
  • Medicine, Biology
    Cancer control : journal of the Moffitt Cancer Center
  • 2007
TLDR
Angiogenic agents inhibiting VEGF and PDGF have shown promising clinical results and targeting more than one pathway by combining different agents may increase the antitumor activity of these drugs.
Nucleic acids as therapeutic agents.
TLDR
The exquisite specificity and versatility of therapeutic oligonucleotides attracts a great deal of research and resources that will certainly convert them in the TNA of choice for treating cancer and viral diseases in the near future.
Antiangiogenic drugs: current knowledge and new approaches to cancer therapy.
TLDR
An overview of current attempts to inhibit tumour angiogenesis for cancer therapy is provided.
...
...

References

SHOWING 1-10 OF 22 REFERENCES
A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.
  • A. Adjei, G. Dy, F. A. Dorr
  • Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
TLDR
The combination of gemcitabine and ISIS 2503 was well tolerated and clinically active in patients with advanced solid tumors and one partial response was documented in a heavily pretreated patient with metastatic breast cancer.
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
  • C. Rudin, M. Kozloff, E. Vokes
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
The combination of G3139, carboplatin, and etoposide is well tolerated and results in an encouraging response rate and time to progression in patients with extensive stage SCLC.
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
  • K. Margolin, M. Gordon, J. Breed
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
TLDR
RhuMAbVEGF can be safely combined with chemotherapy at doses associated with VEGF blockade and without apparent synergistic toxicity, and should be evaluated in randomized treatment trials.
Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models
TLDR
The addition of TNP-470/minocycline to treatment with paclitaxel and carboplatin resulted in increased antitumor activity and efficacy and further investigation of this combination is warranted.
Pharmacokinetics and Tolerability of an Antiangiogenic Ribozyme (ANGIOZYME™) in Healthy Volunteers
TLDR
Ribozyme administration was well tolerated after a single 4‐hour IV infusion of up to 30 mg/m2 or a single SC bolus of 20 mg/ m2, and an absolute SC bioavailability of approximately 69%.
Acute toxicology and pharmacokinetic assessment of a ribozyme (ANGIOZYME) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey.
TLDR
The potential acute toxicity of a ribozyme (ANGIOZYME) targeting the flt-1 vascular endothelial growth factor (VEGF) receptor mRNA was evaluated in cynomolgus monkeys following i.c. and i.v. routes, and there was no clear evidence of ANGIOzYME-related adverse effects.
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
TLDR
The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Phase II Trial of a Paclitaxel-Carboplatin Combination in Recurrent Squamous Cell Carcinoma of the Head and Neck
TLDR
From these data, paclitaxel-carboplatin seems to have an activity in recurrent squamous cell carcinoma of the head and neck, but the high level of toxicity highlights the need to search for a safer chemotherapy combination.
Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors.
  • P. Pavco, K. Bouhana, T. Parry
  • Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2000
TLDR
Data from pharmacodynamic studies testing anti-Flt-1 and anti-KDR ribozymes in animal models of solid tumor growth and metastasis represent the first demonstration that synthetic Ribozymes targeting VEGF receptor mRNA reduced the growth and tumour growth in vivo.
Paclitaxel metabolites in human plasma and urine: identification of 6 alpha-hydroxytaxol, 7-epitaxol and taxol hydrolysis products using liquid chromatography/atmospheric-pressure chemical ionization mass spectrometry.
TLDR
LC/MS with an APCI interface is useful for the characterization and pharmacokinetic analysis of taxoids in biological matrices in patients treated with this new anticancer drug.
...
...